

15 Dec 2023

**Dear Editors,**

**Re: Manuscript MS# 88726**

On behalf of all co-authors, I would like to thank you and the reviewer very much for positive and favorable comments, and constructive suggestions on our manuscript **MS#88726**. We are especially grateful to the reviewer and the editors for their kindness, generosity, and graciousness in providing detailed constructive comments and suggestions for us to improve the quality of our MS.

We have revised the MS strictly according to the reviewer and editors' comments and suggestions. And we have revised them strictly. In the following, we detail our point-by-point responses to these comments and suggestions.

**Suggestions of Reviewer 1#**

**Comments:**

**Point 1: The title of the paper states that sclerosing cholangitis predisposed to cholangiocarcinoma was analyzed. But the paper did not analyze the role of let-7a microRNA inhibition in preventing cholangiocarcinoma.**

**Response:** We feel great thanks for your professional review work on our article. In this paper, the main aim of us was to investigate the therapeutic effects of inhibition of a microRNA let-7a on a DDC-induced mouse model of sclerosing cholangitis. And the primary sclerosing cholangitis (PSC) is characterized by chronic inflammation and it predisposes to cholangiocarcinoma due to lack of effective treatment options. And the study of the role of let-7a microRNA inhibition in preventing cholangiocarcinoma is in

progressing. Maybe the title is not very suitable, according to your nice suggestion, we have minor revised the title and that will not influence the framework of the paper.

**Point 2. The reference list has only 3 sources from the last 3 years. It is recommended to add references to the latest data.**

**Responses:** We sincerely appreciate the valuable comments. We have checked the literature carefully and added more references from the latest data in the revised manuscript.

**Point 3: In conclusion, it is recommended to discuss directions for further research and clinical perspectives of the findings.**

**Responses:** We think this is an excellent suggestion. We have added the discussion of the directions for further research and clinical perspectives of the findings in conclusion.

### **Suggestions and requirement of science editor**

**Specific comments: (1) Please provide the Biostatistics statement. (2) Please provide the Institutional review board statement. (3) Please provide the Informed consent statement. (4) Please provide the Language certificate. (5) Please provide the ARRIVE guidelines. (6) Please provide the Figures cited in the original manuscript in the form of PPT. All text can be edited, including A,B, arrows, etc. With respect to the reference to the Figure, please verify if it is an original image created for the manuscript, if not, please provide the source of the picture and the proof that the Figure has been authorized by the previous publisher or copyright owner to allow it to be redistributed. All legends are incorrectly formatted and require a general title and explanation for each figure. Such as Figure 1 title. A: ; B: ; C: (7) Please obtain permission for the use of picture(s). (8) Please don't include any \*, #, †, §, ‡, ¥, @....in your manuscript;**

Please use superscript numbers for illustration; and for statistical significance, please use superscript letters. Statistical significance is expressed as  $aP < 0.05$ ,  $bP < 0.01$  ( $P > 0.05$  usually does not need to be denoted). If there are other series of P values,  $cP < 0.05$  and  $dP < 0.01$  are used, and a third series of P values is expressed as  $eP < 0.05$  and  $fP < 0.01$ . (9) The “Article Highlights” section is missing. Please add the “Article Highlights” section at the end of the main text (and directly before the References). (10) Please provide all fund documents. (11) Abbreviations other than special types of words such as COVID-19 and SARS-CoV-2 are not allowed in the article title, and no more than 18 words are allowed. The title cannot start with "the, a, an".

**Responses:** Thanks for your suggestion. We have made the necessary modifications and provided the corresponding materials as requested. **About the language, our author of this manuscript (Miriam Nkesichi Kalagbor) is a native English speaker from the USA to help polish our article, and she is a post-doctor in our group. She has been revised the MS thoroughly.** And we hope the revised manuscript could be acceptable for you.

We tried our best to improve the manuscript and made some changes marked in yellow in revised paper which will not influence the content and framework of the paper. We appreciate for Editors/Reviewers' warm work earnestly, and hope the correction will meet with approval. Once again, thank you very much for your comments and suggestions.

We sincerely hope that the MS has been revised to your satisfaction. We are looking forward to seeing the acceptance of the revised MS for publication in your esteemed journal.

Sincerely yours,

Chao Yan

PhD, Associate Professor,

Jiangsu Key Laboratory of Immunity and Metabolism,  
Department of Pathogenic Biology and Immunology, Xuzhou Medical University,  
Xuzhou, Jiangsu Province, PR China.

Tel: +86-18752108439

Email: [yanchao6957@xzhmu.edu.cn](mailto:yanchao6957@xzhmu.edu.cn); [yanchao6957@163.com](mailto:yanchao6957@163.com) ;